Screener
Beta Bionics BBNX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 58.3%+4.4pp | 57.2%+3.2pp | 55.4%+0.3pp | 54.5%+0.5pp | 53.9%-0.3pp | |
| Operating margin | -69.8%+10.4pp | -70.1%+7.8pp | -71.5%-2.0pp | -77.4%+8.9pp | -80.1%+35.1pp | |
| Net margin | -61.3%+32.7pp | -60.3%+41.4pp | -73%+11.1pp | -87.9%+12.1pp | -94%+50.1pp | |
| Returns | ||||||
| Return on equity | -26.2%— | -22.7%— | —— | —— | —— | |
| Return on invested capital | -33.8%— | -29.4%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.4×— | 0.3×— | 0.4×-0.1× | —— | —— | |
| Liquidity | ||||||
| Current ratio | 8.9×-5.8× | 10.7×-5.2× | 8.7×+2.4× | 10.6×— | 14.7×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $5.76-17.2% | $6.10-40.2% | $7.10+118% | $6.76+120% | $6.95+119% | |
| Valuation | ||||||
| Market capitalization | $1.02B+14.3% | $444.71M— | $1.34B— | $863.75M— | $681.56M— | |
| Price / sales | 8.6×-1.5× | 4×— | 13.4×— | 9.8×— | 8.7×— | |
| Price / book | 4×+0.9× | 1.6×— | 4.7×— | 2.9×— | 2.3×— |
FAQ
- What are Beta Bionics's profit margins?
- Beta Bionics (BBNX) runs a 58.3% gross margin and a -69.8% operating margin, with a -61.3% net margin.
- Where do Beta Bionics's ratios come from?
- Every ratio is computed from Beta Bionics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
